Daicel Corporation (TYO:4202)

Market Cap	374.05B +6.0%
Revenue (ttm)	578.81B +0.4%
Net Income	41.14B -26.1%
EPS	155.25 -23.2%
Shares Out	256.99M
PE Ratio	9.38
Forward PE	7.83
Dividend	60.00 (3.95%)
Ex-Dividend Date	Mar 30, 2026

Volume	818,400
Average Volume	980,095
Open	1,500.00
Previous Close	1,455.50
Day's Range	1,478.50 - 1,521.50
52-Week Range	1,057.50 - 1,658.00
Beta	0.29
RSI	43.32
Earnings Date	Feb 5, 2026

About Daicel

Daicel Corporation engages in the materials, medical/healthcare, smart, safety, and engineering plastics businesses in Japan and internationally. The company offers medical/healthcare products, including BELLOCEA S7, a spherical cellulose acetate particle; FLAVOCELL S-Equol; Urolithin A; polyglycerols; konjac ceramide; excipients for foods; chiral columns and reagents; and Actranza lab, as well as separation and analytical services. It also provides performance films, solvents for electronic materials, cycloaliphatic epoxies, polymers for photo...

• Industry: Specialty Chemicals
• Sector: Materials
• Founded: 1919
• Employees: 11,178
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4202

Financial Performance

In fiscal year 2025, Daicel's revenue was 586.53 billion, an increase of 5.10% compared to the previous year's 558.06 billion. Earnings were 49.48 billion, a decrease of -11.38%.